Efficacy of Guselkumab for Treating Psoriatic Arthritis

Feb 23, 04:20 PM

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a Network Meta-Analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a network meta-analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Time Stamps: 
1:13: An overview of the latest analysis of TREMFYA
5:10: Can you tell me a bit more about the study design of the network meta-analysis (NMA) that was presented? 
7:35: You briefly touched on the findings of the NMA, can you go into some more detail about the precise findings? 
10:52: Were you surprised by the results of the study?
11:28: What is the clinical significance of these results?
12:28: Were there any strengths or limitations of the study that you'd like to highlight?
13:50: Is there anything else you'd like rheumatologists now before we wrap up?